Slideshow
Here’s a brief look at 6 medications for rheumatologic disorders that were newly approved in the second half of 2018.
Women Who Give Birth After Infertility Have Elevated Risk of Systemic Rheumatic Disease
Emerging Agents in the Treatment of Rheumatic Diseases
Denosumab Biosimilar Demonstrates Equivalent Efficacy, Safety in Phase 3 Trial
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
FDA Approves Ustekinumab (STELARA) Biosimilar for Crohn’s, UC, Psoriasis, PsA
Real-World Study Confirms Similar Efficacy of Guselkumab and IL-17i for PsA